A recent study published in BMC Pharmacology & Toxicology aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versuspioglitazone or rosiglitazone. Here, online databases were searched for studies comparing vildagliptin with pioglitazone/rosiglitazone. Overall, 2396 patients were analyzed, of which 1486 were treated with vildagliptin and pioglitazone, while 910 patients were treated with rosiglitazone. It was observed that vildagliptin and pioglitazone/rosiglitazone were both associated with similar overall adverse drug events. However, peripheral edema and weight gain was significantly higher with pioglitazone/rosiglitazone. Moreover, when pioglitazone and rosiglitazone were separately compared with vildagliptin, peripheral edema and weight gain were markedly lower with vildagliptin. Therefore, it was inferred that vildagliptin renders considerably lower weight gain and peripheral edema in comparison, and is acceptable for the treatment of patients with T2DM.